Predictive Biomarkers: Progress on the Road to Personalized Cancer Immunotherapy
- 6 April 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 113 (12) , 1601-1603
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanomaScience Translational Medicine, 2018
- Genetic Mechanisms of Immune Evasion in Colorectal CancerCancer Discovery, 2018
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin LymphomaJournal of Clinical Oncology, 2018
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerJournal of Clinical Oncology, 2018
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyThe Lancet Oncology, 2017
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017
- Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaNew England Journal of Medicine, 2016
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyNature Communications, 2016
- PD-1/PD-L1 inhibitorsCurrent Opinion in Pharmacology, 2015
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityNature, 2015